Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22411
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Walker, Steven T | - |
dc.contributor.author | Grigg, Samuel E | - |
dc.contributor.author | Kirkpatrick, Carl | - |
dc.contributor.author | Urbancic, Karen F | - |
dc.contributor.author | Cohen, Emma | - |
dc.contributor.author | Grigg, Andrew P | - |
dc.contributor.author | Trubiano, Jason | - |
dc.date | 2020-01-07 | - |
dc.date.accessioned | 2020-01-13T04:06:14Z | - |
dc.date.available | 2020-01-13T04:06:14Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.citation | Supportive Care in Cancer 2020; 28(9): 4337-4343 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22411 | - |
dc.description.abstract | To assess the impact of a pathway allowing nurse initiation of first dose intravenous (IV) antibiotics on time to antibiotic administration (TTA) in adult inpatients with febrile neutropenia (FN). This study evaluated the impact on TTA of a clinical pathway (November 2017 to April 2018) allowing nurse initiation of pre-prescribed antibiotics in adult haematology patients with FN, compared with a prior cohort (November 2016 to April 2017) in which antibiotics were only prescribed and administered after medical review. The primary endpoint for comparison was TTA, calculated as the time between the first recorded fever and IV antibiotic administration. Secondary endpoints included appropriateness of initial antibiotic choice, 30-day all-cause mortality and admission to intensive care unit (ICU). Forty-seven eligible FN episodes in 40 patients and 61 episodes in 52 patients were evaluated in the pre- and post-implementation groups, respectively. Baseline characteristics were comparable between groups. Median (IQR) TTA, in the pre-implementation group [66 min (40-100 min)] was significantly prolonged versus post-implementation group [29 min (20-41 min); p < 0.001]. A significantly higher proportion of episodes were administered appropriate initial antibiotics in the post-versus pre-implementation groups (100% vs. 89%, p = 0.03). There was no significant change in 30-day all-cause mortality (0% vs. 5%, p = 0.3) or ICU admission within 48 h of fever (0% vs. 2%, p > 0.99) between pre- and post-implementation groups, respectively. A pathway allowing nurse initiation of pre-prescribed antibiotic orders for FN significantly reduced TTA from first recorded fever and increased the proportion of appropriate initial antibiotic choices without significantly impacting on patient outcomes. | en |
dc.language.iso | eng | - |
dc.subject | Febrile neutropenia | en |
dc.subject | Haematology | en |
dc.subject | Nurse-initiated antibiotics | en |
dc.subject | Time to antibiotic administration | en |
dc.title | Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia. | en |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Supportive Care in Cancer | en |
dc.identifier.affiliation | General Medicine | en |
dc.identifier.affiliation | The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre; The National Centre for Antimicrobial Stewardship, Melbourne Health, Victoria, Australia | en |
dc.identifier.affiliation | Department of Clinical Haematology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia | en |
dc.identifier.affiliation | Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Melbourne, Australia | en |
dc.identifier.affiliation | Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1007/s00520-019-05290-2 | en |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-2988-6234 | en |
dc.identifier.orcid | 0000-0002-6116-6595 | en |
dc.identifier.orcid | 0000-0002-9275-578X | en |
dc.identifier.orcid | 0000-0002-5111-6367 | en |
dc.identifier.pubmedid | 31912358 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Cohen, Emma | - |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | General Medicine | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Infectious Diseases | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Centre for Antibiotic Allergy and Research | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.